Guiwen Guan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Guiwen Guan has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Xiangmei Chen
Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences Peking University Health Science Center Beijing China
4 shared publicationsTing Zhang
Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences Peking University Health Science Center Beijing China
3 shared publications- Fengmin Lu
Department of Microbiology and Infectious Disease Center School of Basic Medical Sciences Peking University Health Science Center Beijing China
2 shared publications Jing Yang
Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou Guangdong China
2 shared publications- Na Gao
Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 shared publications - Qiyi Zhao
Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
Integrated Transcriptomic and Translatomic Profiling Reveals Noncanonical RNA Junctions and Hidden Coding Potential in Porcine Epidemic Diarrhea Virus
Porcine epidemic diarrhea virus (PEDV) poses a major threat to the global swine industry. Although coronavirus discontinuous transcription is well characterized, the classical model cannot fully explain the diversity of viral RNA junctions, while conventional genome annotations may underestimate viral protein-coding capacity. To address these gaps, we integrated time-resolved RNA sequencing (RNA-seq), cycloheximide (CHX)- and harringtonine (HAR)-treated ribosome profiling (Ribo-seq), comparative genomics, and peptide mass spectrometry to investigate PEDV RNA expression and hidden coding potential. RNA-seq revealed that, at 3 hours post-infection (hpi), the 3’ genomic region exhibited strong relative coverage enrichment, whereas the relative contribution of the 5’ replicase-coding region increased rapidly between 3 and 5 hpi, suggesting a possible transition from sgRNA-dominated RNA accumulation toward enhanced genomic RNA replication. Genome-wide junction analysis identified 43,635 distinct noncanonical RNA junctions, although canonical sgRNA junctions accounted for 95.5% of all junction-supporting reads. Several abundant noncanonical sgRNAs were predicted to generate novel coding products, including N-x4, N-x2, M-x3, and M-x2, short peptides encoded within the 3’ untranslated region (UTR), and two distinct N-terminally truncated S proteins, thereby expanding the potential coding repertoire of PEDV. Genome-wide reading-frame analysis uncovered a pronounced asymmetry in hidden coding potential, identifying 68 overlapping open reading frames (ORFs) longer than 40 amino acids in the +1 reading frame, compared with only three in the +2 frame. Ribo-seq further revealed a progressive redistribution of viral ribosome occupancy toward structural protein-coding regions during the later stages of infection. By integrating HAR-associated translation initiation-site enrichment with CHX-based ORF-level translation analysis, we identified several noncanonical ORFs with strong translation-associated evidence, including N-x1, N-x2, S-x1, and ORF1b-x13. Moreover, peptide mass spectrometry detected a characteristic peptide corresponding to N-x1 in infected samples, providing independent proteomic evidence for the expression of this previously unannotated viral protein. Together, these findings uncover extensive noncanonical RNA synthesis and hidden protein-coding capacity in PEDV, establishing a foundation for understanding novel viral gene expression strategies and their potential evolutionary and pathogenic significance.
Open AccessIntegrated Transcriptomic and Translatomic Profiling Reveals Noncanonical RNA Junctions and Hidden Coding Potential in Porcine Epidemic Diarrhea Virus
Porcine epidemic diarrhea virus (PEDV) poses a major threat to the global swine industry. Although coronavirus discontinuous transcription is well characterized, the classical model cannot fully explain the diversity of viral RNA junctions, while conventional genome annotations may underestimate viral protein-coding capacity. To address these gaps, we integrated time-resolved RNA sequencing (RNA-seq), cycloheximide (CHX)- and harringtonine (HAR)-treated ribosome profiling (Ribo-seq), comparative genomics, and peptide mass spectrometry to investigate PEDV RNA expression and hidden coding potential. RNA-seq revealed that, at 3 hours post-infection (hpi), the 3’ genomic region exhibited strong relative coverage enrichment, whereas the relative contribution of the 5’ replicase-coding region increased rapidly between 3 and 5 hpi, suggesting a possible transition from sgRNA-dominated RNA accumulation toward enhanced genomic RNA replication. Genome-wide junction analysis identified 43,635 distinct noncanonical RNA junctions, although canonical sgRNA junctions accounted for 95.5% of all junction-supporting reads. Several abundant noncanonical sgRNAs were predicted to generate novel coding products, including N-x4, N-x2, M-x3, and M-x2, short peptides encoded within the 3’ untranslated region (UTR), and two distinct N-terminally truncated S proteins, thereby expanding the potential coding repertoire of PEDV. Genome-wide reading-frame analysis uncovered a pronounced asymmetry in hidden coding potential, identifying 68 overlapping open reading frames (ORFs) longer than 40 amino acids in the +1 reading frame, compared with only three in the +2 frame. Ribo-seq further revealed a progressive redistribution of viral ribosome occupancy toward structural protein-coding regions during the later stages of infection. By integrating HAR-associated translation initiation-site enrichment with CHX-based ORF-level translation analysis, we identified several noncanonical ORFs with strong translation-associated evidence, including N-x1, N-x2, S-x1, and ORF1b-x13. Moreover, peptide mass spectrometry detected a characteristic peptide corresponding to N-x1 in infected samples, providing independent proteomic evidence for the expression of this previously unannotated viral protein. Together, these findings uncover extensive noncanonical RNA synthesis and hidden protein-coding capacity in PEDV, establishing a foundation for understanding novel viral gene expression strategies and their potential evolutionary and pathogenic significance.
- 31 July 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (8) , e70505
AUF1 Is a Novel Negative Regulator for Hepatitis B Virus Replication Acting Through a Posttranscriptional Manner
Elucidating the molecular mechanisms underlying hepatitis B virus (HBV)‐host interactions will hold promise for identifying novel therapeutic targets for HBV. This study aims to investigate the functional interplay and regulatory mechanisms between HBV and the AU‐rich element RNA‐binding protein 1 (AUF1). We demonstrate that AUF1 inhibits HBV replication and expression in HBV‐infected HepG2‐NTCP cells, HepG2 cells cotransfected with prcccDNA and pCMV‐Cre plasmids, and HepAD38 cells. Mechanistically, AUF1 reduces HBV RNA levels post‐transcriptionally without altering the transcriptional levels. This suppression occurs primarily through accelerated RNA decay, while translation efficiency remains unaffected. RNA immunoprecipitation confirms AUF1 associates with HBV RNA at multiple binding sites. However, AUF1 and human antigen R (HuR) neither compete for HBV RNA binding nor exhibit antagonistic regulatory functions. Intriguingly, HBV replication significantly reduces intracellular AUF1 protein levels without affecting AUF1 mRNA, suggesting viral induction of AUF1 proteolytic degradation. AUF1 acts as a novel posttranscriptional suppressor of HBV replication via RNA destabilization, revealing a dynamically regulated host‐virus conflict where HBV counteracts AUF1 through protein degradation.
- 31 July 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (8) , e70505
AUF1 Is a Novel Negative Regulator for Hepatitis B Virus Replication Acting Through a Posttranscriptional Manner
Elucidating the molecular mechanisms underlying hepatitis B virus (HBV)‐host interactions will hold promise for identifying novel therapeutic targets for HBV. This study aims to investigate the functional interplay and regulatory mechanisms between HBV and the AU‐rich element RNA‐binding protein 1 (AUF1). We demonstrate that AUF1 inhibits HBV replication and expression in HBV‐infected HepG2‐NTCP cells, HepG2 cells cotransfected with prcccDNA and pCMV‐Cre plasmids, and HepAD38 cells. Mechanistically, AUF1 reduces HBV RNA levels post‐transcriptionally without altering the transcriptional levels. This suppression occurs primarily through accelerated RNA decay, while translation efficiency remains unaffected. RNA immunoprecipitation confirms AUF1 associates with HBV RNA at multiple binding sites. However, AUF1 and human antigen R (HuR) neither compete for HBV RNA binding nor exhibit antagonistic regulatory functions. Intriguingly, HBV replication significantly reduces intracellular AUF1 protein levels without affecting AUF1 mRNA, suggesting viral induction of AUF1 proteolytic degradation. AUF1 acts as a novel posttranscriptional suppressor of HBV replication via RNA destabilization, revealing a dynamically regulated host‐virus conflict where HBV counteracts AUF1 through protein degradation.
- 27 February 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (3) , e70256
Novel Function of NUP153 in HNF4α Transcriptional Upregulation Contributes to Promoting HBV Replication
Hepatitis B virus (HBV) infection remains a major public health problem, causing nearly one million deaths annually. Nucleoporin 153 (NUP153) is known to facilitate the nuclear entry of the human immunodeficiency virus (HIV) nucleocapsids, and recent studies suggest it also plays a role in HBV nucleocapsids nuclear import. We aimed to investigate the impact of NUP153 on HBV replication and its underlying mechanism. NUP153 was knocked down by RNA interference or CRISPR/Cas9‐mediated gene disruption, or overexpressed using an expression plasmid in HBV‐replicating cells and animal model. Luciferase reporter assays were employed to assess the activities of viral or host factor promoters. Cytoplasmic and nuclear fractionation experiments were conducted to analyze the subcellular distribution of proteins and HBV RNA. In the present study, we found that knockdown of NUP153 significantly inhibited HBV replication without affecting the levels of covalently closed circular DNA (cccDNA) in both the prcccDNA/Cre recombinant plasmid system and HepG2‐NTCP cells. Consistent results were observed in a mouse model hydrodynamically injected (HDI) with 1.2 × HBV plasmid. Conversely, NUP153 overexpression markedly increased cccDNA transcription and progeny virus production. Further study revealed that NUP153 enhanced HBV core promoter activity, likely through a hepatocyte nuclear factor 4α (HNF4α)‐dependent mechanism. Mechanistically, ERK signaling was essential for NUP153‐mediated promotion of HNF4α and HBV replication. Additionally, HBV replication significantly upregulated NUP153 mRNA and protein levels in both HBV cell models and HBV‐infected patients. Together, we identify NUP153 as a novel host factor that promotes HBV replication by enhancing cccDNA transcription through the upregulation of HNF4α, suggesting a potential therapeutic strategy for HBV replication.
- 27 February 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (3) , e70256
Novel Function of NUP153 in HNF4α Transcriptional Upregulation Contributes to Promoting HBV Replication
Hepatitis B virus (HBV) infection remains a major public health problem, causing nearly one million deaths annually. Nucleoporin 153 (NUP153) is known to facilitate the nuclear entry of the human immunodeficiency virus (HIV) nucleocapsids, and recent studies suggest it also plays a role in HBV nucleocapsids nuclear import. We aimed to investigate the impact of NUP153 on HBV replication and its underlying mechanism. NUP153 was knocked down by RNA interference or CRISPR/Cas9‐mediated gene disruption, or overexpressed using an expression plasmid in HBV‐replicating cells and animal model. Luciferase reporter assays were employed to assess the activities of viral or host factor promoters. Cytoplasmic and nuclear fractionation experiments were conducted to analyze the subcellular distribution of proteins and HBV RNA. In the present study, we found that knockdown of NUP153 significantly inhibited HBV replication without affecting the levels of covalently closed circular DNA (cccDNA) in both the prcccDNA/Cre recombinant plasmid system and HepG2‐NTCP cells. Consistent results were observed in a mouse model hydrodynamically injected (HDI) with 1.2 × HBV plasmid. Conversely, NUP153 overexpression markedly increased cccDNA transcription and progeny virus production. Further study revealed that NUP153 enhanced HBV core promoter activity, likely through a hepatocyte nuclear factor 4α (HNF4α)‐dependent mechanism. Mechanistically, ERK signaling was essential for NUP153‐mediated promotion of HNF4α and HBV replication. Additionally, HBV replication significantly upregulated NUP153 mRNA and protein levels in both HBV cell models and HBV‐infected patients. Together, we identify NUP153 as a novel host factor that promotes HBV replication by enhancing cccDNA transcription through the upregulation of HNF4α, suggesting a potential therapeutic strategy for HBV replication.
- 20 December 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (12) , e70120
HCC Model Induced by P53 and Pten Knockout in HBV‐Transgenic Mice Mirrors Human HCC at the Transcriptome Level
With a multitude of HCC mouse models available, choosing the one that most closely resembles human HCC can be challenging. This study addresses this gap by conducting a comprehensive transcriptomic similarity analysis of widely used HCC mouse models. In this study, RNA‐seq was performed on a model induced by double knockout of P53 and Pten via CRISPR/Cas9 in HBV‐transgenic mice. Additionally, RNA‐seq data from 2345 various other models induced by different methods were collected from GEO databases. The gene expression profiles, immune microenvironments, and metabolic pathways of these models were compared with those of human HCC. The analysis revealed distinct transcriptomic features among the different models. The HBV + P53&Pten KO model demonstrated the highest overall similarity to human HCC across various parameters. It shared a high degree of overlap in differentially expression genes (DEGs) between tumor and non‐tumor tissues with human HCC, exhibited a transcriptome profile and immune cell infiltration pattern closely resembling human HCC, and showed metabolic alterations similar to those in human HCC. Conversely the DEN + CCl4‐induced model showed the lowest similarity to human HCC in transcriptome profiles and DEGs and exhibited a distinct immune microenvironment with high NK cell infiltration, with minimal metabolic differences between tumor and non‐tumor tissues. This study highlights the importance of selecting appropriate HCC mouse models for research. The HBV + p53&Pten KO model emerged as the most promising due to its remarkable similarity to human HCC across various aspects.
- 20 December 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (12) , e70120
HCC Model Induced by P53 and Pten Knockout in HBV‐Transgenic Mice Mirrors Human HCC at the Transcriptome Level
With a multitude of HCC mouse models available, choosing the one that most closely resembles human HCC can be challenging. This study addresses this gap by conducting a comprehensive transcriptomic similarity analysis of widely used HCC mouse models. In this study, RNA‐seq was performed on a model induced by double knockout of P53 and Pten via CRISPR/Cas9 in HBV‐transgenic mice. Additionally, RNA‐seq data from 2345 various other models induced by different methods were collected from GEO databases. The gene expression profiles, immune microenvironments, and metabolic pathways of these models were compared with those of human HCC. The analysis revealed distinct transcriptomic features among the different models. The HBV + P53&Pten KO model demonstrated the highest overall similarity to human HCC across various parameters. It shared a high degree of overlap in differentially expression genes (DEGs) between tumor and non‐tumor tissues with human HCC, exhibited a transcriptome profile and immune cell infiltration pattern closely resembling human HCC, and showed metabolic alterations similar to those in human HCC. Conversely the DEN + CCl4‐induced model showed the lowest similarity to human HCC in transcriptome profiles and DEGs and exhibited a distinct immune microenvironment with high NK cell infiltration, with minimal metabolic differences between tumor and non‐tumor tissues. This study highlights the importance of selecting appropriate HCC mouse models for research. The HBV + p53&Pten KO model emerged as the most promising due to its remarkable similarity to human HCC across various aspects.
- Open Access
- 23 April 2024
- Published by Wiley
Multi-Omics Panoramic Analysis of HBV Integration, Transcriptional Regulation, and Epigenetic Modifications in PLC/PRF/5 Cell Line
Background: The clearance or transcriptional silencing of integrated HBV DNA is crucial for achieving a functional cure in patients with chronic hepatitis B (CHB) and reducing the risk of hepatocellular carcinoma (HCC) development. The PLC/PRF/5 cell line is commonly used as an in vitro model for studying HBV integration. In this study, we employed a range of multi-omics techniques to gain a panoramic understanding of the characteristics of HBV integration in PLC/PRF/5 cells and to reveal the transcriptional regulatory mechanisms of integrated HBV DNA. Methods: Transcriptome long-read sequencing (ONT) was conducted to analyze and characterize the transcriptional activity of different HBV DNA integration sites in PLC/PRF/5 cells. Additionally, we collected data related to epigenetic regulation, including whole-genome bisulfite sequencing (WGBS), histone chromatin immunoprecipitation sequencing (ChIP-seq), and assays for transposase-accessible chromatin using sequencing (ATAC-seq), to explore the potential mechanisms involved in the transcriptional regulation of integrated HBV DNA. Result: Long-read RNA sequencing analysis revealed significant transcriptional differences at various integration sites in the PLC/PRF/5 cell line, with higher HBV DNA transcription levels at integration sites on chr11, chr13, and the chr13/chr5 fusion chromosome t (13:5). Combining long-read DNA and RNA sequencing results, we found that transcription of integrated HBV DNA generally starts downstream of the SP1, SP2, or XP promoters. ATAC-seq data confirmed that chromatin accessibility has limited influence on the transcription of integrated HBV DNA in the PLC/PRF/5 cell line. Analysis of whole-genome bisulfite sequencing data showed that the methylation intensity of integrated HBV DNA was highly negatively correlated with its transcription level ( r = -0.8929, p = 0.0123). After AzaD treatment, the transcription level of integrated HBV DNA significantly increased, especially for the integration chr17, which had the highest level of methylation. Through ChIP-seq data, we observed the association between histone modification of H3K4me3 and H3K9me3 with the transcription of integrated HBV DNA.
- 23 April 2024
- Published by Wiley
Open AccessMulti-Omics Panoramic Analysis of HBV Integration, Transcriptional Regulation, and Epigenetic Modifications in PLC/PRF/5 Cell Line
Background: The clearance or transcriptional silencing of integrated HBV DNA is crucial for achieving a functional cure in patients with chronic hepatitis B (CHB) and reducing the risk of hepatocellular carcinoma (HCC) development. The PLC/PRF/5 cell line is commonly used as an in vitro model for studying HBV integration. In this study, we employed a range of multi-omics techniques to gain a panoramic understanding of the characteristics of HBV integration in PLC/PRF/5 cells and to reveal the transcriptional regulatory mechanisms of integrated HBV DNA. Methods: Transcriptome long-read sequencing (ONT) was conducted to analyze and characterize the transcriptional activity of different HBV DNA integration sites in PLC/PRF/5 cells. Additionally, we collected data related to epigenetic regulation, including whole-genome bisulfite sequencing (WGBS), histone chromatin immunoprecipitation sequencing (ChIP-seq), and assays for transposase-accessible chromatin using sequencing (ATAC-seq), to explore the potential mechanisms involved in the transcriptional regulation of integrated HBV DNA. Result: Long-read RNA sequencing analysis revealed significant transcriptional differences at various integration sites in the PLC/PRF/5 cell line, with higher HBV DNA transcription levels at integration sites on chr11, chr13, and the chr13/chr5 fusion chromosome t (13:5). Combining long-read DNA and RNA sequencing results, we found that transcription of integrated HBV DNA generally starts downstream of the SP1, SP2, or XP promoters. ATAC-seq data confirmed that chromatin accessibility has limited influence on the transcription of integrated HBV DNA in the PLC/PRF/5 cell line. Analysis of whole-genome bisulfite sequencing data showed that the methylation intensity of integrated HBV DNA was highly negatively correlated with its transcription level ( r = -0.8929, p = 0.0123). After AzaD treatment, the transcription level of integrated HBV DNA significantly increased, especially for the integration chr17, which had the highest level of methylation. Through ChIP-seq data, we observed the association between histone modification of H3K4me3 and H3K9me3 with the transcription of integrated HBV DNA.
- 26 October 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 58 (10) , 1105-1106
Editorial:HBsAgseroclearance after pegylated interferon treatment—The beginning of the end. Authors' reply
- 26 October 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 58 (10) , 1105-1106
Editorial:HBsAgseroclearance after pegylated interferon treatment—The beginning of the end. Authors' reply
- 29 August 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 58 (10) , 1086-1098
Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg‐positive patients with functional cure following PEG‐IFN‐based therapy
Summary: Background: Hepatitis B surface antigen (HBsAg) seroclearance marks regression of hepatitis B virus (HBV) infection. However, more than one‐fifth of patients with functional cure following pegylated interferon‐based therapy may experience HBsAg seroreversion. The mechanisms causing the HBV relapse remain unclear.Aim: To investigate the level and origin of HBV transcripts in patients with functional cure and their role in predicting relapse.Methods: Liver tissue obtained from patients with functional cure, as well as uncured and treatment‐naïve HBeAg‐negative patients with chronic hepatitis B (CHB) were analysed for intrahepatic HBV markers. HBV capture and RNA sequencing were used to detect HBV integration and chimeric transcripts.Results: Covalently closed circular DNA (cccDNA) levels and the proportion of HBsAg‐positive hepatocytes in functionally cured patients were significantly lower than those in uncured and treatment‐naïve HBeAg‐negative patients. Integrated HBV DNA and chimeric transcripts declined in functionally cured patients compared to uncured patients. HBsAg‐positive hepatocytes present in 25.5% of functionally cured patients, while intrahepatic HBV RNA remained in 72.2%. The levels of intrahepatic HBV RNA, integrated HBV DNA, and chimeric transcripts were higher in functionally cured patients with intrahepatic HBsAg than in those without. The residual intrahepatic HBsAg in functionally cured patients was mainly derived from transcriptionally active integrated HBV DNA; meanwhile, trace transcriptional activity of cccDNA could also remain. Two out of four functionally cured patients with intrahepatic HBsAg and trace active cccDNA experienced HBV relapse.Conclusion: Integrated HBV DNA and cccDNA maintain transcriptional activity and maybe involved in HBsAg seroreversion in intrahepatic HBsAg‐positive patients with functional cure and linked to virological relapse.
- 29 August 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 58 (10) , 1086-1098
Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg‐positive patients with functional cure following PEG‐IFN‐based therapy
Summary: Background: Hepatitis B surface antigen (HBsAg) seroclearance marks regression of hepatitis B virus (HBV) infection. However, more than one‐fifth of patients with functional cure following pegylated interferon‐based therapy may experience HBsAg seroreversion. The mechanisms causing the HBV relapse remain unclear.Aim: To investigate the level and origin of HBV transcripts in patients with functional cure and their role in predicting relapse.Methods: Liver tissue obtained from patients with functional cure, as well as uncured and treatment‐naïve HBeAg‐negative patients with chronic hepatitis B (CHB) were analysed for intrahepatic HBV markers. HBV capture and RNA sequencing were used to detect HBV integration and chimeric transcripts.Results: Covalently closed circular DNA (cccDNA) levels and the proportion of HBsAg‐positive hepatocytes in functionally cured patients were significantly lower than those in uncured and treatment‐naïve HBeAg‐negative patients. Integrated HBV DNA and chimeric transcripts declined in functionally cured patients compared to uncured patients. HBsAg‐positive hepatocytes present in 25.5% of functionally cured patients, while intrahepatic HBV RNA remained in 72.2%. The levels of intrahepatic HBV RNA, integrated HBV DNA, and chimeric transcripts were higher in functionally cured patients with intrahepatic HBsAg than in those without. The residual intrahepatic HBsAg in functionally cured patients was mainly derived from transcriptionally active integrated HBV DNA; meanwhile, trace transcriptional activity of cccDNA could also remain. Two out of four functionally cured patients with intrahepatic HBsAg and trace active cccDNA experienced HBV relapse.Conclusion: Integrated HBV DNA and cccDNA maintain transcriptional activity and maybe involved in HBsAg seroreversion in intrahepatic HBsAg‐positive patients with functional cure and linked to virological relapse.